SSWM
NVCR icon

Sheets Smith Wealth Management’s NovoCure NVCR Stock Holding History

Sheets Smith Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,692
Closed -$597K – 371
2021
Q2 		$597K Hold
2,692
– – 0.08% 200
2021
Q1 		$356K Hold
2,692
– – 0.05% 255
2020
Q4 		$466K Buy
+2,692
New +$368K 0.07% 211

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sheets Smith Wealth Management's NVCR Position: Q3 2021 in Review

Sheets Smith Wealth Management sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 2,692 shares — an estimated $597K sold.

Sheets Smith Wealth Management first reported a position in NVCR in Q4 2020 and held it in 3 quarters. The position peaked at $597K in Q2 2021. 318 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

  • Sheets Smith Wealth Management reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
  • Sheets Smith Wealth Management sold 2,692 NovoCure shares in Q3 2021, an estimated $597K.
  • Sheets Smith Wealth Management first reported a position in NovoCure in Q4 2020 and held it in 3 quarters.
  • Sheets Smith Wealth Management's NovoCure position peaked at $597K in Q2 2021.
  • 318 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Sheets Smith Wealth Management's 13F filing for Q3 2021, filed 15 Oct 2021.